Drugs / CCW702
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04077021 | Jul 2020 → Oct 2022 | prostate adenocarcinoma | Calibr, a division of Scripps Research | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCW702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04077021 ↗ |
| Route | Subcutaneous | “CCW702 administered subcutaneously QOD” NCT04077021 ↗ |